QuantSignals › Forecasts › REGN
KATY's daily model path, its record on REGN, and the options read. Prices as of the Nov 10, 2026 close · page updated Nov 10, 2026.
Last close
$916.06
Nov 10, 2026 · −0.42% on the day
KATY call
SELL
run Nov 6, 2026
Path end (20 sessions)
$724.02
−19.94% from $904.35
Path range
−19.9% to −1.3%
lowest and highest point of the path
Replay record on REGN
0/3 hits
0% · 3 misses
Options
CHEAP
IV 33% · 0.97× realized
KATY's latest public daily path for Regeneron, from its run on Nov 6, 2026, points down, which KATY labels SELL. Starting from the $904.35 close, the path ends 20 sessions later near $724.02 (−19.94%), around Dec 4, and ranges between −19.94% and −1.25% along the way. That is a model path, not a price target.
Since that run, REGN has closed at $916.06 on Nov 10, 2026, +1.29% from the start, 2 of 20 sessions in. So far the move runs against the path. The call is scored after session 20.
On REGN, KATY's replay record is 0 hits and 3 misses in 3 tested calls (0%), below its 50.1% rate across all tickers. Its most recent completed replay call expected −7.18% and REGN moved +21.14%: a miss on direction.
In options, the at-the-money 2026-12-18 contract trades at 33% implied volatility against about 34% realized, 0.97× realized, so options read cheap. That is a pricing read, not a signal.
Daily closes, with KATY's Nov 6, 2026 path drawn from its start close to its end point; the shaded wedge spans the path's lowest and highest points.
The KATY apps and extension show the newest REGN path as soon as it runs, with the full step-by-step line on the chart. They are free to install; live forecasts need KATY Premium or an FST membership.
Every public REGN path this page has captured, scored on the close 20 sessions after its start: a BUY is a hit if that close is higher, a SELL if it is lower.
| Run | Call | Start close | Path end | Outcome at 20 sessions |
|---|---|---|---|---|
| Nov 6, 2026 | SELL | $904.35 | $724.02 (−19.94%) | Open, 2/20 sessions · +1.29% so far |
0 hits, 3 misses in 3 replayed REGN calls (0% on direction; 0% finished inside the 1.5% band; average path error 8.98%). Across all tickers KATY's replay hit rate is 50.1% over 1,023 calls (BUY > +1.5%, SELL < -1.5% on the 20-step path). Replays re-run the model on past data it did not see; they are not live trades.
KATY re-forecast the 20 sessions that just finished without seeing them. It expected −7.18%; the actual move was +21.14% (direction miss, average path error 13.27%).
| Step | Session | Model path | Actual close | Path vs actual |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | $740.50 | $762.81 | −2.92% |
| 5 | Oct 16, 2026 | $732.82 | $790.74 | −7.32% |
| 10 | Oct 23, 2026 | $722.99 | $805.02 | −10.19% |
| 15 | Oct 30, 2026 | $718.49 | $927.89 | −22.57% |
| 20 | Nov 6, 2026 | $692.94 | $904.35 | −23.38% |
The at-the-money 2026-12-18 REGN option (38 days) is priced at 32.8% implied volatility, 0.97× the stock's realized volatility, which reads cheap. Cheap or rich is a pricing read, not a signal. See the full options-value screen.
KATY's latest public daily path for REGN (run Nov 6, 2026) is SELL: from $904.35 it ends near $724.02 (−19.94%) after 20 sessions. It is a model path, not a price target. The newest path is in the KATY apps (free to install; live forecasts need KATY Premium or an FST membership).
In replay, KATY called the direction of REGN right 0 times and wrong 3 times out of 3 tested calls (0%). Public calls on this page are scored after 20 sessions and listed above, misses included.
KATY is a time-series foundation model that reads the recent daily bars of REGN and draws the most likely path for the next 20 sessions. A path that ends more than 1.5% up is a BUY, more than 1.5% down a SELL, and anything in between is NEUTRAL. It is not investment advice.
KATY draws this forecast on your own charts: in TradingView with the Chrome extension, or on your phone. The extension and apps are free to install; live forecasts need KATY Premium or an FST membership.
Healthcare & biotech
Most viewed
Not investment advice. KATY's output is a model path, not a price target and not a recommendation to buy or sell. Model forecasts are often wrong; the hit and miss counts on this page are shown so you can judge that yourself. Trading involves risk of loss. Data from QS Research; prices are daily closes and may lag.